Cytokinetics (CYTK) Shares Outstanding (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Shares Outstanding (Entity) of $123273.0 for Q1 2026, up 4.03% year-over-year from $118496.0 in Q1 2025, and up 2.64% quarter-over-quarter from $120103.0 in Q4 2025.
Cytokinetics (CYTK) Shares Outstanding (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Shares Outstanding (Entity) for 17 consecutive years, with $123273.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 4.03% year-over-year to $123273.0; the TTM figure through Mar 2026 stood at $123273.0 (up 4.03% YoY), while the FY2025 annual figure was $120103.0, up 7.25% from the prior year.
- Shares Outstanding (Entity) grew to $123273.0 in Q1 2026 per CYTK's latest filing, from $120103.0 in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $123273.0 in Q1 2026 and bottomed at $84996.0 in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $104703.7 across 5 years, with a median of $101924.0 in 2024.
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) gained 22.5% — and 2025, when it rose 1.95%.
- Cytokinetics' Shares Outstanding (Entity) stood at $89825.0 in 2022, then gained by 7.46% to $96524.0 in 2023, then increased by 16.01% to $111979.0 in 2024, then rose by 7.25% to $120103.0 in 2025, then rose by 2.64% to $123273.0 in 2026.
- Business Quant data shows CYTK's Shares Outstanding (Entity) at $123273.0 in Q1 2026, $120103.0 in Q4 2025, and $119982.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | 132.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 132,086.00 |
| Mar 31, 2026 | 123,273.00 |
| Dec 31, 2025 | 120,103.00 |
| Sep 30, 2025 | 119,982.00 |
| Jun 30, 2025 | 119,457.00 |
| Mar 31, 2025 | 118,496.00 |
| Dec 31, 2024 | 111,979.00 |
| Sep 30, 2024 | 117,685.00 |
| Jun 30, 2024 | 109,240.00 |
| Mar 31, 2024 | 101,924.00 |
| Dec 31, 2023 | 96,524.00 |
| Sep 30, 2023 | 96,071.00 |
| Jun 30, 2023 | 95,755.00 |
| Mar 31, 2023 | 95,164.00 |
| Dec 31, 2022 | 89,825.00 |
| Sep 30, 2022 | 93,758.00 |
| Jun 30, 2022 | 85,731.00 |
| Mar 31, 2022 | 84,996.00 |
| Dec 31, 2021 | 76,886.00 |
| Sep 30, 2021 | 80,329.00 |